Company intelligence / Profile preview
Ceruvia Lifesciences
Greenwich, Connecticut, United Statesceruvialifesciences.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ceruvia Lifesciences is advancing psychedelic and non-psychedelic therapies for psychiatric and neurological disorders. Its Phase 2 programs include synthetic psilocybin (SYNP-101) for OCD, alcohol use disorder, and smoking cessation; BOL-148 (NYPRG-101), a non-hallucinogenic LSD analog, is in Phase 1 for headache and substance abuse disorders. Early clinical data show significant and durable improvements in symptoms, especially for OCD and alcohol use disorder.[3][4][10]
- Therapeutic areas
- NeurologyInfectious DiseasesPsychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Yale UniversityNYU Langone’s Department of PsychiatryJefferson University HospitalHannover Medical SchoolUNC Eshelman School of MedicineUsona InstituteHeffter Research InstituteClusterbusters
Beyond the preview
Go deeper on Ceruvia Lifesciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ceruvia Lifesciences.